Last updated: February 26, 2026
What is the current excipient usage for DIURIL?
Chlorothiazide (DIURIL) is a thiazide diuretic primarily used to treat hypertension and edema. The formulation typically includes excipients such as microcrystalline cellulose, cornstarch, magnesium stearate, and sodium lauryl sulfate, which aid in tablet stability, disintegration, and bioavailability.
Typical Formulation Components:
- Active ingredient: Chlorothiazide
- Fillers: Microcrystalline cellulose, lactose monohydrate
- Disintegrants: Croscarmellose sodium
- Binders: Povidone (PVP)
- Lubricants: Magnesium stearate
- Surfactants: Sodium lauryl sulfate
How do excipient strategies impact manufacturing and patent stability?
Excipients influence several factors:
- Bioavailability: Disintegrants and surfactants improve dissolution rates.
- Stability: Protective excipients prevent moisture and light degradation.
- Manufacturability: Flow agents like magnesium stearate optimize compressibility.
- Patentability: Unique excipient combinations or novel delivery systems can extend patent life.
What are potential innovations in excipient selection for DIURIL?
- Enhanced bioavailability formulations: Use of solubilizing agents or lipid-based excipients that increase absorption.
- Controlled-release systems: Matrix or coating excipients to modulate release profiles, improving compliance.
- Taste-masking excipients: For pediatric or patient-administered forms, taste-masking agents improve tolerability.
- Stability-enhancing excipients: Incorporating antioxidants or desiccants to extend shelf life.
What commercial opportunities exist in excipient formulation for DIURIL?
1. Formulation Differentiation
Developing novel controlled-release formulations could command premium pricing and extend patent protection.
2. Extended Patent Life
Innovative excipient combinations or delivery platforms can create new patent filings, delaying generic competition.
3. Pediatric and Patient-Centered Formulations
Taste-masked, liquid, or dispersion forms tailored to specific populations open new market segments.
4. Biosimilar and Generic Development
Standardized excipient strategies that meet regulatory flexibilities facilitate faster approval of generics, capturing market share.
5. Licensing and Partnerships
Collaborations with excipient suppliers can lead to co-developed, patentable formulations, expanding market reach.
What regulatory considerations are associated with excipient modifications?
- Modifications trigger supplemental New Drug Applications (sNDA) or abbreviated new drug applications (ANDA) depending on the region.
- Regulatory agencies such as FDA (USA) and EMA (Europe) require stability data and bioequivalence studies for formulation changes.
- Use of excipients not previously approved for oral tablets demands safety and toxicity data.
How to evaluate the scalability of excipient-based innovations?
- Conduct pilot production runs to measure batch reproducibility.
- Perform stability testing under ICH conditions (25°C/60% RH, 40°C/75% RH).
- Engage with regulators early to validate new excipient safety profiles.
- Use real-world pharmacokinetic data to confirm bioequivalence.
Recap of Opportunities and Risks
| Opportunity |
Risk |
| Formulation innovation (controlled-release) |
Regulatory hurdles and requirement for comprehensive testing |
| Novel excipients or delivery systems |
Higher development costs |
| Expanding into pediatric markets |
Need for taste-masking and safety validation |
| Patents for new excipient combinations |
Potential for patent litigation |
| Entering biosimilar or generic markets |
Market saturation, pricing pressure |
Key Takeaways
- Excipient strategies can extend patent life, improve bioavailability, and provide formulation differentiation.
- Innovations such as controlled-release, taste-masking, and stability-enhancing excipients present clear commercial opportunities.
- Regulatory pathways demand rigorous testing and compliance, especially with formulation modifications.
- Developing new excipient-based formulations can tap into unmet needs in pediatric and special patient populations.
- Collaborations with excipient suppliers and patent filings around novel combinations support market expansion.
5 FAQs
1. Can excipient modifications improve DIURIL's patent life?
Yes. New combinations or delivery systems involving excipients can generate patent filings and extend exclusivity.
2. What are the main regulatory challenges in changing excipients?
Demonstrating safety, stability, and bioequivalence through additional testing and filing processes.
3. Are there market advantages in pediatric formulations of DIURIL?
Yes. Pediatric-friendly forms increase adherence and open access to off-label uses.
4. How significant are controlled-release formulations for DIURIL?
They can reduce dosing frequency, improve patient compliance, and command higher pricing.
5. Which excipients could lead to formulation breakthroughs?
Lipid excipients for solubilization, novel disintegrants for faster dissolution, and taste-masking agents for patient acceptance.
References
[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: Excipients in Drug Products. FDA.
[2] European Medicines Agency. (2021). Reflection Paper on Pharmaceutical Innovation. EMA.
[3] WHO. (2019). Handbook of Nonprescription Drugs. WHO Press.
[4] Katzung, B. G., & Trevor, A. J. (2018). Basic and Clinical Pharmacology (14th ed.). McGraw Hill.
[5] Bloomfield, K. (2020). Novel excipient applications for extended-release formulations. Journal of Pharmaceutical Sciences, 109(2), 648-656.
